Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evogliptin vs active control in patients with impaired renal function and type 2 diabetes
KCT0002982Phase 2Recruiting
- Sponsor
- Dong-A ST
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DA5221-B2 in type 2 diabetes mellitus (T2DM), Renal Insufficiency (RI), albuminuria, sponsored by Dong-A ST. Started Apr 2017; status: recruiting.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)Renal Insufficiency (RI)albuminuria
Beyond the preview
Go deeper on KCT0002982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002982.